The nutrigenetics and pharmacogenetics of vitamin d pathways

Current Pharmacogenomics and Personalized Medicine

Volumn 12, Issue 2, 2014, Pages 89-103

  Awada, Zainab ^a   Ossaily, Safaa ^a   Zgheib, Nathalie K ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Cytochrome P450; Epigenetics; Nutrigenetics; Pharmacogenetics; Vitamin D 25(OH)D

Indexed keywords

25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; CYTOCHROME P450; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ALLELE; ARTICLE; BODY MASS; CYP27B1 GENE; CYP2R1 GENE; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALABSORPTION; NEXT GENERATION SEQUENCING; NUTRIGENOMICS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN BLOOD LEVEL; VITAMIN D RECEPTOR GENE; VITAMIN SUPPLEMENTATION;

EID: 84924116306     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692112666140529002223     Document Type: Article

References (63)

1. [1] Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358(9292): 1500-3.
2. [2] Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Res 2008; 23(7): 974-9.
3. [3] Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93(6): 512-7.
4. [4] Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
5. [5] Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98(7): 451-9.
6. [6] Martinez ME, Giovannucci EL, Colditz GA, et al. Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl. Cancer Inst 1996; 88(19): 1375-82.
7. [7] Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96(2): 252-61.
8. [8] John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999; 8(5): 399-406.
9. [9] Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008; 87(4): 1087S-91S.
10. [10] Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
11. [11] Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16(7): 713-6.
12. [12] Arabi A, El RR, El-Hajj FG. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat Rev Endocrinol 2010; 6(10): 550-61.
13. [13] Shea MK, Benjamin EJ, Dupuis J, et al. Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr 2009; 63(4): 458-64.
14. [14] Karohl C, Su S, Kumari M, et al. Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr 2010; 92(6): 1393-8.
15. [15] Shinkyo R, Sakaki T, Kamakura M, Ohta M, Inouye K. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun 2004; 324(1): 451-7.
16. [16] Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011; 25(4): 531-41.
17. [17] Monticielo OA, Brenol JC, Chies JA, et al. The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25- hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. Lupus 2012; 21(1): 43-52.
18. [18] Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011; 26(7): 1609-16.
19. [19] Yang L, Ma J, Zhang X, Fan Y, Wang L. Protective role of the vitamin D receptor. Cell Immunol 2012; 279(2): 160-6
20. [20] Ferder M, Inserra F, Manucha W, Ferder L. The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system. Am J Physiol Cell Physiol 2013; 304(11): C1027-39.
21. [21] Ahn J, Albanes D, Berndt SI, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30(5): 769-76.
22. [22] Engelman CD, Fingerlin TE, Langefeld CD, et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25- dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008; 93(9): 3381-8.
23. [23] Emerah AA, El-Shal AS. Role of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D level in Egyptian female patients with systemic lupus erythematosus. Mol Biol Rep 2013; 40(11): 6151-62.
24. [24] Signorello LB, Shi J, Cai Q, et al. Common variation in vitamin D pathway genes predicts circulating 25-hydroxyvitamin D Levels among African Americans. PLoS One 2011; 6(12): e28623.
25. [25] Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 2009; 89(2): 634-40.
26. [26] Orton SM, Morris AP, Herrera BM, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008; 88(2): 441-7.
27. [27] Abbas S, Nieters A, Linseisen J, et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res 2008; 10(2): R31.
28. [28] Vupputuri MR, Goswami R, Gupta N, Ray D, Tandon N, Kumar N. Prevalence and functional significance of 25-hydroxyvitamin D deficiency and vitamin D receptor gene polymorphisms in Asian Indians. Am J Clin Nutr 2006; 83(6): 1411-9.
29. [29] Abrams SA, Griffin IJ, Hawthorne KM, et al. Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty. J Bone Miner Res 2005; 20(6): 945-53.
30. [30] Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 2009; 207(1-2): 117-21.
31. [31] Rezende VB, Barbosa F, Jr., Montenegro MF, Sandrim VC, Gerlach RF, Tanus-Santos JE. An interethnic comparison of the distribution of vitamin D receptor genotypes and haplotypes. Clin Chim Acta 2007; 384(1-2): 155-9.
32. [32] Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 2000; 22(2): 203-17.
33. [33] Bu FX, Armas L, Lappe J, et al. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum Genet 2010; 128(5): 549-56.
34. [34] Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer- Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol 2011; 164(5): 741-9.
35. [35] Wjst M, Altmuller J, Faus-Kessler T, Braig C, Bahnweg M, Andre E. Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res 2006; 7: 60.
36. [36] Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376(9736): 180-8.
37. [37] Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19(13): 2739-45.
38. [38] Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. ProcNatlAcadSci USA 2004; 101(20): 7711-5.
39. [39] Levine MA, Dang, Ding, Fischer, Singh R, Thacher T. Tropical rickets in Nigeria: Mutation of the CYP2R1 gene encoding vitamin D 25-hydroxylase as a cause of vitamin D dependent rickets. Bone 2007; 40(6): 60-1.
40. [40] Al Mutair AN, Nasrat GH, Russell DW. Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. J Clin Endocrinol Metab 2012; 97(10): E2022-E2025.
41. [41] Ossaily S, Zgheib NK. The pharmacogenetics of drug metabolizing enzymes in the Lebanese population. Drug Metabol Drug Interact. 2014; 29(2): 81-90.
42. [42] Ramos-Lopez E, Bruck P, Jansen T, Herwig J, Badenhoop K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev 2007; 23(8): 631-6.
43. [43] Lauridsen AL, Vestergaard P, Hermann AP, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 2005; 77(1): 15-22.
44. [44] Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. Exp Clin Endocrinol Diabetes 2006; 114(6): 329-35.
45. [45] Porter TR, Li X, Stephensen CB, et al. Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: finemapping for the GC/DBP gene that encodes the vitamin D-binding protein. Front Genet 2013; 4: 234.
46. [46] Wjst M, Altmuller J, Braig C, Bahnweg M, Andre E. A genomewide linkage scan for 25-OH-D(3) and 1,25-(OH)2-D3 serum levels in asthma families. J Steroid Biochem Mol Biol 2007; 103(3-5): 799-802.
47. [47] Anderson LN, Cotterchio M, Knight JA, Borgida A, Gallinger S, Cleary SP. Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada. PLoS One 2013; 8(6): e66768.
48. [48] Levin GP, Robinson-Cohen C, de Boer IH, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308(18): 1898-905.
49. [49] Clifton-Bligh RJ, Nguyen TV, Au A, et al. Contribution of a common variant in the promoter of the 1-alpha-hydroxylase gene (CYP27B1) to fracture risk in the elderly. Calcif Tissue Int 2011; 88(2): 109-16.
50. [50] Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 2011; 258(9): 1676-82.
51. [51] Zhang Y, Yang S, Liu Y, Ren L. Relationship between polymorphisms in vitamin D metabolism-related genes and the risk of rickets in Han Chinese children. BMC Med Genet 2013; 14: 101.
52. [52] Martin RJ, McKnight AJ, Patterson CC, Sadlier DM, Maxwell AP. A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropathy. Nephrol Dial Transplant 2010; 25(2): 497-503.
53. [53] Arabi A, Zahed L, Mahfoud Z, et al. Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls. Bone 2009; 45(6): 1091-7.
54. [54] Arabi A, Mahfoud Z, Zahed L, El-Onsi L, El-Hajj FG. Effect of age, gender and calciotropic hormones on the relationship between vitamin D receptor gene polymorphisms and bone mineral density. Eur J Clin Nutr 2010; 64(4): 383-91.
55. [55] Didriksen A, Grimnes G, Hutchinson MS, et al. The serum 25- hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. Eur J Endocrinol 2013; 169(5): 559-67.
56. [56] Nimitphong H, Saetung S, Chanprasertyotin S, Chailurkit LO, Ongphiphadhanakul B. Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D(3) or D(2)supplementation. Nutr J 2013; 12: 39.
57. [57] Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem 2009; 42(10-11): 1174-7.
58. [58] Zhang X, Ho SM. Epigenetics meets endocrinology. J Mol Endocrinol 2011; 46(1): R11-R32.
59. [59] Zhu H, Wang X, Shi H, et al. A genome-wide methylation study of severe vitamin D deficiency in African American adolescents. J Pediatr 2013; 162(5): 1004-9.
60. [60] Zhou Y, Zhao LJ, Xu X, et al. DNA methylation levels of CYP2R1 and CYP24A1 predict vitamin D response variation. J Steroid Biochem Mol Biol 2013.
61. [61] Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10(5): 373-88.
62. [62] Lisse TS, Adams JS, Hewison M. Vitamin D and microRNAs in bone. Crit Rev Eukaryot Gene Expr 2013; 23(3): 195-214.
63. [63] Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 2013; 155(1): 27-38.